ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
The Pharma Data
JANUARY 6, 2021
a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. Under the terms of the agreement, ImaginAb will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials. LOS ANGELES , Jan.
Let's personalize your content